Sex: U
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Pyrexia, Vaccination site erythema, Vaccination site pain
Clinical narrative: Moderate malaise/feeling sick present with some interference with activity; Mild fever (100.4 to 101.2 °F) ; Mild injection site pain and no interference with activity/ mild injection site tenderness (tender to touch); Mild injection site redness; Mild injection site swelling; Moderate fatigue with some interference with activity; Mild muscle pain and no interference with activity; Joint pain with some interference with activity; Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting; Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting; Headache that interfered with activity OR required repeated use of a nonprescription pain reliever; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Moderate malaise/feeling sick present with some interference with activity), PYREXIA (Mild fever (100.4 to 101.2 °F) ), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness) and VACCINATION SITE SWELLING (Mild injection site swelling) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Moderate malaise/feeling sick present with some interference with activity), PYREXIA (Mild fever (100.4 to 101.2 °F) ), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain with some interference with activity), VOMITING (Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting), NAUSEA (Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting) and HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever). At the time of the report, MALAISE (Moderate malaise/feeling sick present with some interference with activity), PYREXIA (Mild fever (100.4 to 101.2 °F) ), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain with some interference with activity), VOMITING (Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting), NAUSEA (Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting) and HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Fever (100.4-to-101.2 degree Fahrenheit).     The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Patient had experienced mild injection site pain, tenderness (tender to touch), redness, swelling, fever, muscle pain with no interference with activity and moderate fatigue, malaise/feeling sick, Joint pain, headache, nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting anytime during the 2 days after COVID-19 vaccination, which occurred on Wednesday, December 20, 2023, and Thursday, December 21, 2023.  Concomitant medications were not reported.   No treatment medication was provided by the reporter.      This case was linked to US-MODERNATX, INC.-MOD-2024-756099 ( Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Same reporter